Pandemic Billing Under Fire as Michigan Lab Settles Medicare Case

Gloved hand holding a COVID-19 test tube beside a stylized DNA helix — Photo: Mongkolchon Akesin / Shutterstock

A Michigan lab just paid nearly $6.5 million over COVID test bills for seniors that the government says were never asked for or never received.

Story Snapshot

A West Bloomfield lab will pay $6,494,290 to resolve federal False Claims Act allegations tied to Medicare COVID test billing.
Investigators say the lab billed Medicare for at-home COVID tests that beneficiaries never requested and never got.
The settlement is civil, not criminal, and makes clear there is no official finding of liability or proven fraud.
This case is one of many pandemic-era lab billing actions, adding to public doubts about how COVID money was handled.

What Orchard Laboratories Is Accused Of Doing

Federal officials say Orchard Laboratories Corporation, a clinical reference lab in West Bloomfield, Michigan, took part in a special Medicare program that paid for at-home COVID tests during the pandemic. Under that program, from April 4, 2022 through May 11, 2023, Medicare allowed eligible seniors to get up to eight over-the-counter COVID tests per month from approved providers. Guidance from the Centers for Medicare and Medicaid Services said labs could bill only for tests that people both requested and received. Prosecutors say Orchard instead billed Medicare for tests that were never requested or never delivered.

Complaints from the public sparked a federal investigation into Orchard’s billing. The United States Attorney’s Office for the Eastern District of Michigan led the case, working with the Federal Bureau of Investigation (FBI) and the Office of Inspector General for the Department of Health and Human Services. These offices said Orchard submitted claims for over-the-counter COVID tests that did not match real patient orders or shipments. In simple terms, the government’s allegation is that Medicare was charged for products that never reached the people whose names were on the bills.

The $6.5 Million Settlement And What It Really Means

To end the civil case, Orchard agreed to pay $6,494,290 to the federal government under the False Claims Act, a law used to recover money when officials think programs like Medicare were billed improperly. The settlement covers claims from roughly March 1 through May 11, 2023, the final stretch of the at-home test program. Importantly, officials and news reports stress that this agreement resolves allegations only and does not include any court finding that Orchard committed fraud. There is no public document where the lab admits to knowingly cheating the system.

The lack of a trial or detailed public complaint leaves some key facts unknown. The reporting does not show how many claims were allegedly false, how investigators sampled bills, or whether problems were caused by intent, sloppy systems, or confusion over fast-changing COVID rules. Like many False Claims Act settlements, this deal looks like a negotiated compromise: the government gets money back and a public warning, while the lab avoids the risk and cost of a long fight in court. Still, the size of the payment and the strong language from prosecutors send a signal that federal agencies view the conduct as serious.

A Bigger Pattern: COVID Money, Labs, And Public Trust

This Michigan story fits into a wider crackdown on health care billing during and after COVID. In 2025, the same U.S. Attorney’s Office charged a chief executive and a medical director in a separate $500 million COVID testing scheme, alleging bills for tests that were never actually done. In 2026, the Department of Justice announced a $19.2 million settlement with Magnolia Diagnostics over claims it billed Medicare for medically unnecessary respiratory tests tied to COVID testing in senior living centers. Other labs around the country have paid millions to resolve claims of unnecessary drug tests, extra panels, or duplicate billing.

Michigan Lab Coughs Up $6.5M to Settle COVID-19 Test Billing Fraud Claims https://t.co/d953jIcgCe

— Ω Paladin (@omega_paladin) July 30, 2026

For many Americans, both conservative and liberal, these cases feed a deep worry: huge sums flowed through health programs during COVID, but watchdogs are only now tracing where that money went and how much may have been wasted or misused. People who already think the “deep state” or entrenched health bureaucracy puts profit and politics over patients see stories like Orchard’s as proof their doubts are justified. At the same time, honest doctors, lab workers, and patients who followed the rules may feel anger that some players seemed to treat a crisis as a cash grab, further eroding trust in federal programs meant to protect public health.

Why This Matters Beyond One Michigan Lab

For conservatives who oppose big government programs and for liberals who fear corporate abuse, this case underscores a shared concern: oversight often arrives late, after damage is done. Medicare created an at-home test benefit to help seniors stay safe, but billing controls were clearly weak enough that officials now say some providers charged for tests people did not get. When government money can be tapped that easily, many citizens feel the system is rigged for insiders—lawyers, executives, and bureaucrats—rather than for taxpayers who fund it.

False Claims Act cases are supposed to protect public funds, yet they rarely give the public a full, clear picture of what went wrong. Settlements often end without trials, without clear admissions, and without detailed public data on how many fake or improper claims were found. That leaves room for frustration on both sides: some see enforcement as too soft on powerful actors, while others worry honest mistakes are punished in a political climate where agencies must show “results.” What is plain is that COVID-era health spending will be under the microscope for years, and that stories like Orchard’s will keep fueling doubts about whether the federal government can run large programs without waste, fraud, or favoritism.